Bioventus plans to acquire CartiHeal for $500 million

Bioventus has made a $50 million escrow payment signaling its intent to acquire Israeli medtech company CartiHeal for approximately $500 million, pending FDA approval of CartiHeal's Agili-C implant.

“We believe this product could be a strong alternative for the approximately 650,000 U.S. patients annually receiving microfracture or debridement along with other cartilage treatment options.”beckersspine.com

• 1 source
• beckersspine.comBioventus lines up another $500M acquisition — 5 details - Becker’s Spine ReviewAlan CondonAug 31, 2021

Summarized from public sources; check the original articles before acting on it.